ATP. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Presents New Data That Demonstrate Tango Antisense Oligonucleotides Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy
Akero Therapeutics Appoints Yuan Xu to its Board of Directors